Investor Relations

Latest Financial Results

Q3 2018

Quarter Ended Sep 30, 2018

Latest Annual Filing

Fiscal Year Ended Dec 31, 2017

View Filing

Stock Information

Company Overview

Cell Source is a biotechnology company focused on developing cell therapy treatments based on the management of immune tolerance. The company's patented "Veto-Cell" technology represents a major breakthrough in immune system management - safe and selective "tolerizing" of immune response. This technology addresses one of the most fundamental challenges in human immunology: how to tune immune response so that it tolerates specific "desirable" foreign cells while continuing to attack all other potential threats.

Our mission is to revolutionize the fields of transplantation, cancer treatment and reversal of vital organ disease, utilizing our breakthrough immune tolerance and organ regeneration technologies, in order to save lives and fulfill the inspiring promise of immunotherapy.

Investor Presentation

Investor Presentation

Download Investor Presentation

Leadership

Having accumulated decades of collective experience across a variety of fields, our leadership team is the source of our success.

Investor Contact Information

Company

Cell Source, Inc.
57 W 57th Street
Suite 400
New York, NY 10019
Toll-Free: +1 646.612.7554
T: 646-612-7554
F: 646-612-7545
info@cell-source.com

Investor Relations

T: 888-315-4650
info@cell-source.com

Market Data copyright © 2019 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.